Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy

被引：42

作者：

Awasthi, Rakesh ^{[1
,5
]}

Maier, Harald J. ^{[2
]}

Zhang, Jie ^{[3
]}

Lim, Stephen ^{[4
]}

机构：

[1] Novartis Inst Biomed Res, E Hanover, NJ USA

[2] Novartis Pharm AG, Oncol & Hematol, Global Drug Dev, Basel, Switzerland

[3] Novartis Serv Inc, Cell & Gene Unit, E Hanover, NJ USA

[4] Novartis Pharmaceut, US Med Affairs, Oncol, E Hanover, NJ USA

[5] Novartis Inst Biomed Res, Oncol & Hematol, One Hlth Plaza, E Hanover, NJ 07936 USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 01期

关键词：

Cell and gene therapy; CAR-T therapy; clinical development; immunotherapy; leukemia; lymphoma; B-CELL LYMPHOMA; UNITED-STATES; OUTCOMES; JULIET; MANAGEMENT; 2ND-LINE;

D O I：

10.1080/21645515.2023.2210046

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah (R) (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.

引用

页数：8

共 47 条

[1]

[Anonymous], 2018, CHIM ANT REC T CELL

[2] Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL [J].

Awasthi, Rakesh ;

Pacaud, Lida ;

Waldron, Edward ;

Tam, Constantine S. ;

Jager, Ulrich ;

Borchmann, Peter ;

Jaglowski, Samantha ;

Foley, Stephen Ronan ;

van Besien, Koen ;

Wagner-Johnston, Nina D. ;

Kersten, Marie Jose ;

Schuster, Stephen J. ;

Salles, Gilles ;

Maziarz, Richard T. ;

Anak, Ozlem ;

del Corral, Christopher ;

Chu, Jufen ;

Gershgorin, Irina ;

Pruteanu-Malinici, Iulian ;

Chakraborty, Abhijit ;

Mueller, Karen Thudium ;

Waller, Edmund K. .

BLOOD ADVANCES, 2020, 4 (03) :560-572

[3] Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients [J].

Awasthi, Rakesh ;

Mueller, Karen Thudium ;

Yanik, Gregory A. ;

Tam, Constantine S. ;

Rives, Susana ;

McGuirk, Joseph P. ;

Pulsipher, Michael A. ;

Boyer, Michael W. ;

Jaeger, Ulrich ;

Baruchel, Andre ;

Myers, Gary Douglas ;

Balke-Want, Hyatt ;

Schuster, Stephen J. ;

Stefanski, Heather ;

Bishop, Michael R. ;

Waldron, Edward R. ;

Anak, Ozlem ;

Chakraborty, Abhijit ;

Bleickardt, Eric ;

Wong, Stephane ;

Pacaud, Lida Bubuteishvili ;

Waller, Edmund K. ;

Maude, Shannon L. .

BLOOD, 2018, 132

[4] CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments [J].

Baumgardner, James ;

Everson, Katie ;

Brauer, Michelle ;

Zhang, Jie ;

Hao, Yanni ;

Liu, Jamae ;

Lakdawalla, Darius N. .

BLOOD, 2018, 132

[5] Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements? [J].

Bear, Adham S. ;

Morgan, Richard A. ;

Cornetta, Kenneth ;

June, Carl H. ;

Binder-Scholl, Gwendolyn ;

Dudley, Mark E. ;

Feldman, Steven A. ;

Rosenberg, Steven A. ;

Shurtleff, Sheila A. ;

Rooney, Cliona M. ;

Heslop, Helen E. ;

Dotti, Gianpietro .

MOLECULAR THERAPY, 2012, 20 (02) :246-249

[6] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma [J].

Bishop, M. R. ;

Dickinson, M. ;

Purtill, D. ;

Barba, P. ;

Santoro, A. ;

Hamad, N. ;

Kato, K. ;

Sureda, A. ;

Greil, R. ;

Thieblemont, C. ;

Morschhauser, F. ;

Janz, M. ;

Flinn, I ;

Rabitsch, W. ;

Kwong, Y-L ;

Kersten, M. J. ;

Minnema, M. C. ;

Holte, H. ;

Chan, E. H. L. ;

Martinez-Lopez, J. ;

Mueller, A. M. S. ;

Maziarz, R. T. ;

McGuirk, J. P. ;

Bachy, E. ;

Le Gouill, S. ;

Dreyling, M. ;

Harigae, H. ;

Bond, D. ;

Andreadis, C. ;

McSweeney, P. ;

Kharfan-Dabaja, M. ;

Newsome, S. ;

Degtyarev, E. ;

Awasthi, R. ;

del Corral, C. ;

Andreola, G. ;

Masood, A. ;

Schuster, S. J. ;

Jaeger, U. ;

Borchmann, P. ;

Westin, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) :629-639

[7] Toxicities of chimeric antigen receptor T cells: recognition and management [J].

Brudno, Jennifer N. ;

Kochenderfer, James N. .

BLOOD, 2016, 127 (26) :3321-3330

[8] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[9]

Dreyling M., 2022, AM SOC HEM ASH ANN M

[10]

Flinn I.W., 2021, Blood, V138, P740, DOI [10.1182/blood-2021-146268, DOI 10.1182/BLOOD-2021-146268]

← 1 2 3 4 5 →